Pancreatic cancer

Lancet

Volumn 363, Issue 9414, 2004, Pages 1049-1057

  Li, Donghui ^a   Xie, Keping ^a   Wolff, Robert ^a   Abbruzzese, James L ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; CARCINOGEN; CELECOXIB; CETUXIMAB; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GEMCITABINE TRIPHOSPHATE; I KAPPA B; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; ORGANIC SOLVENT; ORGANOCHLORINE DERIVATIVE; OXALIPLATIN; PACLITAXEL; PREGNANCY SPECIFIC BETA1 GLYCOPROTEIN; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN INHIBITOR; RAF PROTEIN; ROFECOXIB; SEMAXANIB; TRASTUZUMAB;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG POTENCY; GENE INACTIVATION; GENE MUTATION; GENETIC DISORDER; HUMAN; INOPERABLE CANCER; META ANALYSIS; METASTASIS; ONCOGENE K RAS; PANCREAS CANCER; PANCREATICODUODENECTOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SMOKING HABIT; STENT; SURVIVAL TIME; TOXICITY; TUMOR SUPPRESSOR GENE;

EID: 1642588228     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)15841-8     Document Type: Conference Paper

References (103)

1. Jemal A., Murray T., Samuels A., et al. Cancer statistics, 2003. CA Cancer J Clin. 53:2003;5-26.
2. Anderson K.E., Potter J.D., Mack T.M. Pancreatic cancer. Schottenfeld D., Fraumeni J.F. Jr. Cancer epidemiology and prevention. 1996;725-771 Oxford University Press, Oxford.
3. Fryzek J.P., Garabrant D.H., Greenson J.K., Schottenfeld D. A review of the epidemiology and pathology of pancreas cancer. Gastrointest Cancer. 2:1997;99-110.
4. Hruban R.H., Petersen G.M., Ha P.K., Kern S.E. Genetics of pancreatic cancer: from genes to families. Surg Oncol Clin N Am. 7:1998;1-23.
5. Schenk M., Schwartz A.G., O'Neal E., et al. Garabrant familial risk of pancreatic cancer. J Natl Cancer Inst. 93:2001;640-644.
6. Ji B.T., Chow W.H., Gridley G., et al. Dietary factors and the risk of pancreatic cancer: a case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev. 4:1995;885-893.
7. Ghadirian P., Baillargeon J., Simard A., et al. Food habits and pancreatic cancer: a case-control study of the francophone community in Montreal, Canada. Cancer Epidemiol Biomarkers Prev. 4:1995;895-899.
8. Stolzenberg-Solomon R.Z., Pietinen P., Barrett M.J., Taylor P.R., Virtamo J., Albanes D. Dietary and other methyl-group availability factors and pancreatic cancer risk in a cohort of male smokers. Am J Epidemiol. 153:2001;680-687.
9. Kauppinen T., Partanen T., Degerth R., et al. Pancreatic cancer and occupational exposures. Epidemiology. 6:1995;498-502.
10. Garabrani D.H., Held J., Langholz B., et al. DDT and related compounds and risk of pancreatic cancer. J Natl Cancer Inst. 84:1992;764-771.
11. Fryzek J., Garabrant D.H., Harlow S.D., et al. A case-control study of self-reported exposures to pesticides and pancreas cancer in Southern Michigan. Int J Cancer. 72:1997;62-67.
12. Wang M.Y., Abbruzzese J.L., Friess H., et al. DNA adducts in human pancreatic tissues and their potential role in carcinogenesis. Cancer Res. 58:1998;38-41.
13. Li D., Firozi P.F., Zhang W.Q., et al. DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. Mutat Res. 513:2002;37-48.
14. Thompson P.A., Seyedi F., Lang N.P., et al. Comparison of DNA adduct levels associated with exogenous and endogenous exposures in human pancreas in relation to metabolic genotype. Mutat Res. 424:1999;263-274.
15. Kadlubar F.F., Anderson K.E., Häussermann S., et al. Comparison of DNA adduct levels associated with oxidative stress in human pancreas. Mutat Res. 405:1998;125-133.
16. Bartsch H., Malaveille C., Lowenfels A.B., et al. Genetic polymorphism of N-acetyltransferases, glutathione S-transferase M1 and NAD(P)H:quinone oxidoreductase in relation to malignant and benign pancreatic disease risk: the International Pancreatic Disease Study Group. Eur J Cancer Prev. 7:1998;215-223.
17. Liu G., Ghadirian P., Vesprini D., et al. Polymorphisms in GSTM1, GSTT1 and CYP1A1 and risk of pancreatic adenocarcinoma. Br J Cancer. 82:2000;1646-1649.
18. Duell E.J., Holly E.A., Bracci P.M., Liu M., Wiencke J.K., Kelsey K.T. A population-based, case-control study of polymorphisms in carcinogen- metabolizing genes, smoking, and pancreatic adenocarcinoma risk. J Natl Cancer Inst. 94:2002;297-306.
19. Duell E.J., Holly E.A., Bracci P.M., Wiencke J.K., Kelsey K.T. A population-based study of the Arg399Gln polymorphism in X-ray repair cross-complementing group 1 (XRCC1) and risk of pancreatic adenocarcinoma. Cancer Res. 62:2002;4630-4636.
20. Jiao L., Firozi P.F., Connor T., Li D. Codon 143 polymorphism of AGT gene in pancreatic cancer. Proc Am Assoc Cancer Res. 42:2001;A1844.
21. Malats N., Porta M., Corominas J.M., et al. K-ras mutations in exocrine pancreatic cancer: association with clinico-pathological characteristics and with tobacco and alcohol consumption. Int J Cancer. 70:1997;661-667.
22. Berger D.H., Chang H., Wood M., et al. Mutational activation of K-ras in non-neoplastic exocrine pancreatic lesions in relation to cigarette smoking status. Cancer. 85:1999;326-329.
23. Porta M., Malats N., Jariod M., et al. Serum concentrations of organochlorine compounds and K-ras mutations in exocrine pancreatic cancer. Lancet. 354:1999;2125-2129.
24. Alguacil J., Porta M., Malats N., et al. Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer. Carcinogenesis. 23:2002;101-106.
25. Sohn T.A., Yeo C.J. The molecular genetics of pancreatic ductal carcinoma: a review. Surg Oncol. 9:2000;95-101.
26. Sakorafas G.H., Tsiotos G.G. Molecular biology of pancreatic cancer: potential clinical implications. BioDrugs. 15:2001;439-452.
27. Hruban R.H., Goggins M., Parsons J., Kern S.E. Progression model for pancreatic cancer. Clin Cancer Res. 6:2000;2969-2972.
28. Almoguerra C., Shibata D., Forrester K., et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 53:1988;549-554.
29. Wenger F.A., Zieren J., Peter F.J., Jacobi C.A., Muller J.M. K-ras mutations in tissue and stool samples from patients with pancreatic cancer and chronic pancreatitis. Langenbecks Arch Surg. 384:1999;181-186.
30. Uehara H., Nakaizumi A., Tatsuta M., et al. Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: comparison with K-ras mutations. Am J Gastroenterol. 94:1999;2513-2518.
31. Caldas C., Hahn S.A., da Costa L.T., et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genetics. 8:1994;27-32.
32. Schutte M., Hruban R.H., Geradts J., et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res. 57:1997;3126-3130.
33. Wilentz R.E., Iacobuzio-Donahue C.A., Aragani P., et al. Loss of expression of DPC4 in pancreatic intrapithelial neoplasia (PanIN): evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res. 60:2000;2002-2006.
34. Hahn S.A., Schutte M., Hoque ATMS, et al. DPC4, a candidate tumor-suppressor gene at 18q21.1. Science. 271:1996;350-353.
35. Su G.H., Hilgers W., Shekher M.C., et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res. 58:1998;2339-2342.
36. Su G.H., Hruban R.H., Bansal R.K., et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol. 154:1999;1835-1884.
37. Ozkelik H., Schmocker B., Di Nicola N., et al. Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients. Nat Genet. 16:1997;17-18.
38. Goggins M., Schutte M., Lu J., et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 56:1996;5360-5364.
39. Goggins M., Hruban R.H., Kern S.E. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol. 156:2000;1767-1771.
40. Rozenblum E., Schutte M., Goggins M., et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res. 57:1997;1731-1734.
41. Korc M. Role of growth factors in pancreatic cancer. Surg Oncol Clin N Am. 7:1998;25-41.
42. Luo J., Guo P., Matsuda K., et al. Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int J Cancer. 92:2001;361-369.
43. Shi Q., Le X., Peng Z., et al. Constitutive Sp1 activity is essential for differential constitutive expression of vascular endothelial growth factor in human pancreatic adenocarcinoma. Cancer Res. 61:2001;4143-4154.
44. Yamanaka Y., Friess H., Buchler M., et al. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res. 53:1993;5289-5296.
45. Kleeff J., Ishiwata T., Friess H., et al. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene. 18:1999;5363-5372.
46. Blanchard JA, 2nd, Barve S., Joshi-Barve S., Talwalker R., Gates L.K. Jr. Cytokine production by CAPAN-1 and CAPAN-2 cell lines. Dig Dis Sci. 45:2000;927-932.
47. Saito K., Ishikura H., Kishimoto T., et al. Interleukin-6 produced by pancreatic carcinoma cells enhances humoral immune responses against tumor cells: a possible event in tumor regression. Int J Cancer. 75:1998;284-289.
48. Watanabe N., Tsuji N., Kobayashi D., et al. Endogenous tumor necrosis factor functions as a resistant factor against hyperthermic cytotoxicity in pancreatic carcinoma cells via enhancement of the heart shock element-binding activity of heat shock factor 1. Chemotherapy. 43:1997;406-414.
49. Shi Q., Abbruzzese J., Huang S., Fidler I.J., Xie K. Constitutive and inducible interleukin-8 expression by hypoxia and acidosis renders human pancreatic cancer cells more tumorigenic and metastatic. Clin Cancer Res. 5:1999;3711-3721.
50. Shi Q., Le X., Wang B., et al. Regulation of vascular endothelial growth factor expression by acidosis in human cancer cells. Oncogene. 20:2001;3751-3756.
51. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev. 12:2001;375-391.
52. Neufeld G., Cohen T., Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:1999;9-22.
53. Rak J., Filmus J., Finkenzeller G., Grugel S., Marme D., Kerbel R.S. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 14:1995;263-277.
54. Tischer E., Mitchell R., Hartman T., et al. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing. J Biol Chem. 266:1991;11947-11954.
55. Wei D., Le X., Zheng L., et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene. 22:2003;319-329.
56. Le X., Shi Q., Wang B., et al. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res. 20:2000;1532-1540.
57. Evans D.B., Abbruzzese J.L., Rich T.R. Cancer of the pancreas. DeVita V.T., Hellman S., Rosenberg S.A. Cancer principles and practice of oncology. 5th edn :1997;1054-1087 Lippincott Raven, Philadelphia.
58. Lin A. Pancreatic carcinoma as a cause of unexplained pancreatitis: report of ten cases. Ann Intern Med. 113:1990;166-167.
59. Pisters P.W., Hudec W.A., Hess K.R., et al. Effect of preoperative biliary decompression on pancreaticoduodenectomy-associated morbidity in 300 consecutive patients. Ann Surg. 234:2001;47-55.
60. Sewnath M.E., Karsten T.M., Prins M.H., et al. A meta-analysis on the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg. 236:2002;17-27.
61. Pisters P.W., Lee J.E., Vauthey J.N., Evans D.B. Comment and perspective on Sewnath and colleagues' recent meta-analysis of the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg. 237:2003;594-595.
62. Gouma D.J., Obertop H. Comment and perspective on Sewnath and colleagues' recent meta-analysis of the efficacy of preoperative biliary drainage for tumors causing obstructive jaundice. Ann Surg. 237:2003;595-596.
63. Davids P.H., Groen A.K., Rauws E.A., et al. Randomized trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 340:1992;1488-1492.
64. Di Stasi M., Lencioni R., Solmi L., et al. Ultrasound-guided fine needle biopsy of pancreatic masses: results of a multicenter study. Am J Gastroenterol. 93:1998;1329-1333.
65. Gress F., Gottlieb K., Sherman S., Lehman G. Endoscopic ultrasonography-guided fine-needle aspiration biopsy of suspected pancreatic cancer. Ann Intern Med. 134:2001;459-464.
66. Fuhrman G.M., Charnsangavej C., Abbruzzese J.L., et al. Thin-section contrast-enhanced computed tomography accurately predicts the resectability of malignant pancreatic neoplasms. Am J Surg. 167:1994;104-111.
67. Millikan K.W., Deziel D.J., Silverstein J.C., et al. Prognostic factors associated with resectable adenocarcinoma of the head of the pancreas. Am Surg. 65:1999;618-624.
68. Jimenez R.E., Warshaw A.L., Fernandez-Del Castillo C. Laparoscopy and peritoneal cytology in the staging of pancreatic cancer. J Hepatobiliary Pancreat Surg. 7:2000;15-20.
69. Yeo C.J., Cameron J.L., Lillemore K.D., et al. Pancreaticoduodenectomy for cancer of the head of the pancreas: 201 patients. Ann Surg. 221:1995;721.
70. Lieberman M.D., Kilburn H., Lindsey M., et al. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg. 222:1995;638-645.
71. Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer. 59:1987;2006-2010.
72. Klinkenbijl J.H., Jeekel J., Sahmoud T., et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection for the cancer of the pancreas and peri-ampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg. 230:1999;776-784.
73. Neoptolemos J.P., Dunn J.A., Stocken D.D., et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 358:2001;1576-1585.
74. Neoptolemos J.P., Stocken D., Dunn J.A. ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas. Ann Surg. 236:2002;694-696.
75. Evans D.B., Hess K.R., Pisters P.W. ESPAC-1 trial of adjuvant therapy for resectable adenocarcinoma of the pancreas. Ann Surg. 236:2002;694-696.
76. Abrams R.A., Lillemoe K.D., Piantadosi S. Continuing controversy over adjuvant therapy of pancreatic cancer. Lancet. 358:2001;1565-1566.
77. Neoptolemos J.P., Cunningham D., Friess H., et al. Adjuvant therapy in pancreatic cancer: historical and current perspectives. Ann Oncol. 14:2003;675-692.
78. Moertel C.G., Frytak S., Hahn R.G., et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation + 5-fluorouracil. Cancer. 48:1981;1705-1710.
79. Minsky B.D., Hilaris B., Fuks Z. The role of radiation therapy in the control of pain from pancreatic carcinoma. J Pain Symptom Manage. 3:1988;199-205.
80. Burris HA III, Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 15:1997;2403-2413.
81. Rothenberg M.L., Moore M.J., Cripps M.C., et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 7:1996;347-353.
82. Hoffman J.P., Lipsitz S., Pisansky T., Weese J.L., Solin L., Benson A.B. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol. 16:1998;317-323.
83. White R., Lee C., Anscher M., et al. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas. Ann Surg Oncol. 6:1999;38-45.
84. Spitz F.R., Abbruzzese J.L., Lee J.E., et al. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J Clin Oncol. 15:1997;928-937.
85. Pisters P.W., Wolff R.A., Janjan N.A., et al. Preoperative paclitaxel and concurrent rapid-fractionation radiation for resectable pancreatic adenocarcinoma: toxicities, histologic response rates, and event-free outcome. J Clin Oncol. 20:2002;2537-2544.
86. Wolff RA, Evans DB, Crane CH, et al. Initial results of pre- operative gemcitabine-based chemoradiation for resectable pancreatic adenocarcinoma. Proc Am Soc Clin Oncol 2002; 21: 130a (abstr 516).
87. Wolff R.A., Evans D.B., Gravel D.M., et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res. 7:2001;2246-2253.
88. Blackstock A.W., Bernard S.A., Richards F., et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol. 17:1999;2208-2212.
89. McGinn C.J., Zalupski M.M., Shureiqi I., et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 19:2001;4202-4208.
90. Ryan D.P., Kulke M.H., Fuchs C.S., et al. A phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma. Cancer. 94:2002;97-103.
91. Philip P.A., Zalupski M.M., Vaitkevicius V.K., et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 92:2001;569-577.
92. Louvet C., Andre T., Lledo G., et al. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study. J Clin Oncol. 20:2002;1512-1518.
93. Louvet C., Andre T., Hammel P., et al. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol. 12:2001;675-679.
94. Rocha Lima C.M., Savarese D., Bruckner H., et al. Irinotecan plus gemcitabine induces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol. 20:2002;1182-1191.
95. Colucci G., Giuliani F., Gebbia V., et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 94:2002;902-910.
96. Berlin J.D., Catalano P., Thomas J.P., et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol. 20:2002;3270-3275.
97. Stehlin J.S., Giovanella B.C., Natelson E.A., et al. A study of 9-nitrocamptothecin (RFS 2000) in patients with advanced pancreatic cancer. Int J Oncol. 14:1999;821-831.
98. Sharma S., Kemeny N., Schwartz G.K., et al. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin Cancer Res. 7:2001;3963-3970.
99. Fan Z., Mendelsohn J. Therapeutic application of anti-growth factor receptor antibodies. Curr Opin Oncol. 10:1998;67-73.
100. Van Cutsem E, Karasek P, Oettle H, et al. Phase III trial comparing gemcitabine plus R115777 (Zarnestra) versus gemcitabine plus placebo in advanced pancreatic cancer (PC). Proc Ann Meeting Am Soc Clin Oncol 2002, 21: 130 (abstr).
101. Abbruzzese JL, Rosenberg A, Xiong Q, et al: Phase II study of anti-epidermal growth factor receptor cetuximab (IM-C225) in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol 2001; 20: 130a (abstr 518).
102. Safron H, Ramanathan R, Schwartz J, et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc Am Soc Clin Oncol 2001; 20: 130a (abstr 517).
103. Bramhall S.R., Schulz J., Nemunaitis J., et al. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 87:2002;161-167.